No­vo backs 'break­through' an­ti­fun­gal play­er's $60M round — with a fo­cus on rare mold in­fec­tions

The plight of an­tibi­otics de­vel­op­ers has been well doc­u­ment­ed: chron­i­cal­ly un­der­fund­ed re­search, daunt­ing sci­en­tif­ic chal­lenges, and lit­tle com­mer­cial up­side even for the ones that make …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER